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FUNGSI NEUROKOGNITIF DALAM PENGGUNA DAUN KETUM 
(MITRAGYNA SPECIOSA KORTH) DI BAHAGIAN UTARA 
SEMENANJUNG MALAYSIA 
ABSTRAK 
Penyalahgunaan Ketum (Mitragyna speciosa Korth) telah meningkat sejak 
kebelakangan ini di Malaysia. Banyak kajian farmakologi berkenaan kesan ketum ke 
atas haiwan telah dijalankan. Namun kajian corak pengunaan ketum ke atas fungsi 
neuropsikologi manusia adalah terhad.  
Untuk mengukur fungsi neurokognitif pengguna daun ketum di bahagian utara 
semenanjung Malaysia dan membandingkan dengan subjek sihat yang tidak 
menggunakan dadah (kumpulan kawalan) serta dengan penagih heroin. 
Membandingkan fungsi neurokognitif pengguna daun ketum jangka pendek dan 
jangka panjang.  
Kajian keratan lintang telah dijalankan di tiga negeri yang terletak di bahagian utara 
semenanjung Malaysia, menggunakan kaedah persampelan bertujuan dan 
persampelan rujukan rantaian, di mana sebanyak 116 peserta (41 penagih heroin, 43 
pengguna daun ketum aktif, dan 32 peserta yang bebas dari penyalahgunaan dadah) 
terlibat dalam kajian ini. Lima kajian neuropsikologi bukan lisan (Digit Span Test, 
Block Design Test, Ravens Progressive Matrices Test, Benton Visual Form 
Discrimination Test, and Rey-Osterrieth Complex Figure Test) telah diuji  ke atas 
semua peserta.  
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Semua peserta adalah lelaki yang berumur antara 18-65 tahun. Peserta heroin 
berpendidikan rendah, bujang, menganggur dengan berpendapatan rendah 
berbanding dengan dua kumpulan yang lain. Hasil kajian menunjukkan bahawa 
pengguna daun ketum menunjukkan prestasi yang kurang dalam kebolehan persepsi 
visuospatial yang diukur dengan ujian ROCF berbanding kumpulan pengguna 
heroin. Perbezaan signifikan juga telah dikesan diantara kumpulan pengguna heroin 
dan kumpulan kawalan dalam aspek tumpuan menggunakan ukuran ujian “Digit 
Forward”. Perbandingan pengguna daun ketum jangka pendek dan panjang 
menunjukan bahawa pengguna daun ketum jangka panjang tidak menunjukkan 
masalah di bahagian hujah analogi, fungsi eksekutif, dan memori visual.      
Walaupun tiada bukti kukuh kemerosotan dalam fungsi neurokognitif pengguna daun 
ketum dalam kajian ini, tetapi kajian menunjukkan bahawa terdapat kemerosotan 
dalam keupayaan persepsi visuospatial yang akan menjejaskan pelbagai tugasan 
harian seperti membaca, menulis, mengira dan memandu. Kesimpulan tidak dapat 
dibuat untuk mengaitkan bahawa kemerosotan yang berlaku pada pengguna daun 
ketum adalah akibat langsung dari penggunaan daun tersebut. Kemungkinan 
kemerosotan tersebut telah berlaku sebelum mereka mula menggunakan daun ketum. 
Oleh itu, disyorkan supaya kajian prospektif bersama dengan kajian teknik 
pengimejan otak dilaksanakan untuk membuktikan bahawa daun ketum tidak atau 
mempunyai kesan minima terhadap fungsi kognitif manusia.   
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NEUROCOGNITIVE FUNCTIONING IN KETUM (MITRAGYNA SPECIOSA 
KORTH) LEAF USERS IN NORTHERN PARTS OF PENINSULAR 
MALAYSIA 
ABSTRACT 
Abuse of ketum (Mitragyna speciosa Korth) has increased recently in Malaysia. 
While there are extensive pharmacological studies of ketum effects on animals, 
human studies on patterns of neuropsychological function of ketum leaf users are 
limited.  
To measure the neurocognitive function of ketum users in the northern parts of 
peninsular Malaysia and compare it with that of healthy non-drug users (control 
group) and heroin dependents, also to compare the neurocognitive function of long 
term and short term ketum users. 
A cross sectional study conducted in three northern states of peninsular Malaysia 
using purposive sampling and chain referral methods and total of 116 participants 
(41 heroin dependents, 43 active ketum users, and 32 non drug users) were included. 
Five non verbal neuropsychological tests (Digit Span test, Block Design test, Ravens 
Progressive Matrices test, Benton Visual Form Discrimination test, and Rey-
Osterrieth Complex Figure Test) were administered in all participants. 
All participants were males aged 18-65 years. Heroin participants were less educated, 
single, and more unemployed with lower income levels than the other two groups. 
Results showed a significantly poorer performance by ketum users on visuospatial 
perception ability measured by ROCF test compared to the heroin group. 
xx 
 
Significant difference was also found between heroin and control group on attention 
measured by digits forward test. Comparing long-term and short-term ketum users 
revealed that domains of analogical reasoning, executive functioning, and visual 
memory are not impaired in long-term ketum users.  
Despite no evidence of substantial impairment in neurocognitive function among 
ketum users in this study, there was a significant impairment in their visuospatial 
perception ability which affects many daily tasks such as reading, writing, arithmetic, 
and driving.  There is no definite conclusion that the impairment in ketum users is a 
direct result of their ketum use. There is a possibility that these impairments were 
present in the users even before the initiation of their addiction. Further prospective 
studies together with brain imaging techniques are recommended to prove no or 
minimal effects of ketum use on human cognitive function. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Drug Abuse in the World 
It is estimated that in 2009, 3.3% to 6.1% of the world’s aged 15-64 population 
(149 to 272 million people in the world), used some kind of substances in the past 
year (United Nations Office of Drugs and Crime [UNODC], 2011). Estimations also 
show that in the same year, half of this population were current drug users who used 
drugs at least once in the previous month. Cannabis is reported to be the most widely 
used illicit drug followed by amphetamine-type stimulants (ATS) and opioids 
including opium and heroin. Trends of heroin use in almost all areas of the world are 
mostly stable or downward while use of synthetic and prescription drugs is reported 
to be increasing (UNODC, 2011).  
According to WHO, 148 countries reported injecting drug use of which 120 of 
them reported HIV infection amongst this population (World Health Organization 
[WHO], 2011). In 2009, there were an estimated 33.3 million people (31.4 million – 
35.3 million) living with HIV (Figure 1.1), 2.6 million new HIV infections, and 1.8 
million AIDS-related deaths (United Nations program on HIV/AIDS [UNAIDS], 2010). 
Over 7000 new HIV infections a day reported in 2009 and about 6000 were in adults 
aged 15 years and older, of whom almost 51% were among women and about 41% 
were among young (15-24 years) people (UNAIDS, 2010).    
According to the World Drug Report 2011, 11 to 21 million people within the 
age range of 15-64 are injecting drugs. Approximately 17.9% of drug users who 
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inject their drugs (2.8 million people) are HIV positive. This shows that one fifth of 
injecting drug users are living with HIV. It is also estimated that about half (45.2 % - 
55.3%) of the injecting drug users are infected by hepatitis C virus (UNODC, 2011). 
Also 104,000 to 263,000 deaths per year is estimated to be related or associated with 
drug use and more than half are because of overdose (UNODC, 2011).  
 
 
Source. (UNAIDS, 2010) 
Figure 1.1. Adults and children estimated to be living with HIV in the world 
 
Although there was a steady decrease in the global cultivation of opium poppy 
from 2007 (235,700 ha) to 2009 (185,900 ha), global opium cultivation has increased 
slightly from 185,900 ha in 2009 to 195,700 ha in 2010 (Figure 1.2). The major of 
opium which is cultivated in Afghanistan remained stable and the global increasing 
trend is mainly due to cultivation in Myanmar with an increase of 20%. However, 
opium production in the world has been reduced from 7,853 in 2009 to 4,860 in 2010 
due to the disease of poppy plants in Afghanistan (UNODC, 2011).  
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Source: (UNODC, 2011) 
Figure 1.2. Global opium poppy cultivation (ha), 1990-2010 
 
It was reported in the World Drug Report 2010 that drug use is shifting towards 
new drugs and new markets. The report indicated that compared to the developing 
countries where drug use is increasing, in the developed countries drug use has 
stabilized. It is also reported that abuse of amphetamine-type stimulants (ATS) and 
prescription drugs are growing all over the world (UNODC, 2010). Figure 1.3 shows 
long-term trends in the volume of seizures for all major drug types according to the 
World Drug Report 2011 published by UNODC.  
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1.2 Drug Abuse Definition 
Drug abuse is the habitual use of any chemical substance to alter the state of 
the person’s body or mind for non medical purposes. There are various systems for 
classifying drugs, for instance by origin (those that come from plants, such as the 
opiates), by therapeutic effects, by the site of drug action (which parts of the body 
physical changes due to the drug are appeared, for example by this classification 
alcohol is a depressant and cocaine is a stimulant drug), by chemical structure, by 
mechanism of action or by street name (Maisto, Galizio, & Connors, 2010).  
 
 
Source. (UNODC, 2011) 
Figure 1.3. Trends in the volume of seizures, by main drug categories 
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1.3 Drug Abuse in Malaysia 
Heroin epidemic in Malaysia began in the late 1970 and is present until today 
(Chawarski, Mazlan, & Schottenfeld, 2006). There are nearly 12- 21 million people 
who used opiates in the world and from this total 75% used heroin. The key 
consumption markets for opiates are Europe and Asia. In 2009, heroin was the 
principal drug used in countries including China, Malaysia, Myanmar, Singapore, 
and Vietnam (UNODC, 2011).  
According to the Malaysian department of statistics (DOS) online services total 
population of Malaysia is about 28,607,000. In Malaysia from 1988 to 1998, 162,750 
drug addicts were identified and 88,527 of them were recognized as first time users. 
This means that approximately 0.73% of Malaysia’s population were drug addicts at 
that time (Karofi, 2005). In 2006 the total number of drug users recorded by the 
AADK (Agensi Antidadah Kebangsaan) was 300,241 people, about 1.1% of 
Malaysia’s population.  
According to the last report of the International Narcotics Control Board 
(INCB), which was released in 2009, the most commonly abused drug in Malaysia is 
heroin. Based on this report about 61 percent of drug users in the country abuse 
heroin and 120,000 of them inject their drugs (International Narcotics Control Board 
[INCB], 2009). 
Abuse of some drugs increased in 2011 compared to the same period in the 
previous year. This is evident from the drugs that are seized by Malaysian 
enforcement agencies (Royal Malaysia police, Royal Malaysian Customs and the 
Ministry of Health Malaysia). Some of these drugs are listed as: raw opium, 
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methamphetamine, ecstasy tablet, heroin, and ketum (AADK, 2011). Detailed 
information is presented in Table 1.1.  
 
Table 1.1 
 Type of drugs used in Malaysia in 2011 (January-October) and 2010 
Drugs  2011 2010 Index 
Heroin base (kg) 254.45 30.54 ↑ 
Heroin No.3 (kg) 390.65 216.01 ↑ 
Heroin No.4 (kg) 30.6 30.584 ↑ 
Marijuana (kg) 984 1006.13 ↓ 
Raw opium (kg) 0.74 0.01 ↑ 
Cook opium (kg) 0.12 4.36 ↓ 
Cocaine (kg) 1.76 20.57 ↓ 
Methamphetamine (kg) 992.18 788.1 ↑ 
Ecstasy powder (kg) 26.45 100.86 ↓ 
Ecstasy tablet (N) 96205 37088 ↑ 
Yaba tablet (N) 250534 84649 ↑ 
Psychotropic tablet (N) 374329 264486 ↑ 
Eramin 5 (N) 1079403 2012177 ↓ 
Ketamine (kg) 184.27 263.92 ↓ 
Codeine (liter) 2295.22 27185.39 ↓ 
Ketum (liter) 85058.35 6484.36 ↑ 
Ketum (kg) 2784.21 1637.55 ↑ 
Source. (AADK, 2011) 
 
Figure 1.4 describes the number of addicts detected in all state capitals in 
Malaysia during January-October 2011. Numbers are low because following harm 
reduction (HR) approaches that are being implemented in Malaysia, most of the drug 
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users attended in the Needle and Syringe Exchange Program (NSEP) and Methadone 
Maintenance Therapy (MMT) program and not many drug users were arrested since 
then (NSEP was introduced in 2006 and MMT was introduced in 2005 in Malaysia). 
Georgetown (capital of Penang state) is amongst the states which have high numbers 
(645) of newly detected addicts (AADK, 2011).  
It should be mentioned that in addition to the synthetic drugs being abused in 
Malaysia, there are also natural substances that are being abused. One of these 
substances is Mitragyna speciosa Korth (ketum) which is more prevalent in the rural 
areas especially in the northern states of peninsular Malaysia and based on the last 
AADK report (January- October 2011) its abuse increased in 2011 compared to the 
same period previous year.  
 
Source.  (AADK, 2011) 
Figure 1.4.  Drug distribution in all state capitals for January-October 2011 
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1.4 Ketum 
Ketum “biak” is a regional name for Mitragyna speciosa Korth in Malaysia 
(Figure 1.5). In Thailand it is usually called kratom. Mitragyna speciosa is a psycho-
stimulant plant belongs to the Rubiaceae family and Mitragyna genus, in the same 
family as coffee tree. It is found natively in Southeast Asia and is cultivated 
especially in central and southern parts of Thailand and northern parts of peninsular 
Malaysia. It is a tropical and non-seasonal plant which is sensitive to drought and 
cold (Harizal, Mansor, Hasnan, Tharakan, & Abdullah, 2010). 
Ketum leaves were traditionally used to alleviate diarrhoea, fever, cough, 
diabetes, and pain. They were also used for their stimulant effect to enhance workers 
energy and also for their opium like effects as a substitute for opioids (Chan, Pakiam, 
& Rahim, 2005; Jansen & Prast, 1988; Suwanlert, 1975). 
 
      
Figure1.5. Ketum leaves and trees 
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Earliest pharmacological studies of Mitragyna speciosa were done in 1932 and 
ketum was reported as a treatment for opium withdrawal symptoms (Jansen & Prast, 
1988). Later investigations revealed morphine-like antinociceptive activity of 
Mitragynine alkaloids through the opioid receptors (Matsumoto et al., 1996). 
Mitragynine is the major constituent of Mitragyna speciosa (Kumarnsit, 
Keawpradub, & Nuankaew, 2006) and acts in animals’ gastrointestinal system 
through the opioid receptors (Tsuchiya et al., 2002; Watanabe, Yano, Horie, & 
Yamamoto, 1997). The minor component of Mitragyna speciosa, 7-
Hydroxymitragynine, showed almost 13 times higher potency than morphine in 
animal studies (Matsumoto et al., 2004). This component develops tolerance and 
withdrawal signs through similar opioid mechanisms for morphine (Matsumoto et 
al., 2005). The most potent opioid agonistic effect is found in MGM-9 which 
produces more antinociceptive effects and less adverse effects than morphine 
(Matsumoto et al., 2008). 
In animal behavioral studies, methanol and alkaloid extracts of Mitragyna 
speciosa leaves had no significant effect on pentobarbital-induced sleep or in 
locomotor activity in mice and rats (Moklas et al., 2008; Reanmongkol, Keawpradub, 
& Sawangjaroen, 2007).  
In a recent behavioral study, object placement task which is a valid animal 
model for assessing object recognition in mice, was administered to evaluate the 
effect of mitragynine on this cognitive function and results showed significant 
impairments in the performance of mice (Apryani, Hidayat, Moklas, Fakurazi, & 
Idayu, 2010). 
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1.5 Ketum Studies in Human 
There are limited studies about ketum use in human. Existing studies are upon 
the self reports of participants about using ketum. In a study conducted in Thailand in 
2007, it has been shown that Thai ketum users use ketum primarily to increase their 
work capacity. In another study performed in Malaysia, it has been shown that the 
majority of ketum users use it because it reduces addiction to other drugs, helps to 
improve withdrawal effects from opiate addiction and it is more affordable relative to 
heroin (Vicknasingam, Narayanan, Beng, & Mansor, 2010b). However, these were 
self-reports by ketum users and no objective measures were used to measure these 
effects. 
There are some studies which were done in United States, UK, and Germany 
including a case report of 43 years old male who used ketum to self-manage the 
chronic pain and opioid withdrawal in US (Boyer, Babu, Adkins, McCurdy, & 
Halpern, 2008), a case of young man with intra-hepatic cholestasis following abuse 
of powdered ketum (Kapp, Maurer, Auwärter, Winkelmann, & Hermanns-Clausen, 
2011), and a 44 years male with inpatient detoxification after ketum dependence 
(McWhirter & Morris, 2010). Another study is a study upon internet postings about 
ketum which shows a remarkable increase in the number of ketum users who use 
ketum to modulate opioid withdrawal symptoms in the United States (Boyer, Babu, 
Macalino, & Compton, 2007). 
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1.6 Statement of Problem 
Chronic use of opiates such as heroin and morphine leads to cognitive 
impairments (Cipolli & Galliani, 1987; Guerra, Solé, Camí, & Tobeña, 1987; Hauser, 
Houdi, Turbek, Elde, & Lii, 2000; Spain & Newsom, 1991; Yin et al., 2006). It has 
been shown that abuse of heroin which is one of the most commonly abused drugs is 
linked to poorer performance on attention and memory tasks (Guerra et al., 1987). It 
is suggested that opiates affect structures of the brain that are related to memory and 
learning such as hippocampus and it has been shown that chronic exposure to 
morphine reduces the viability of fetal mouse hippocampus neurons significantly and 
dose dependently (Svensson, Bucht, Hallberg, & Nyberg, 2008). In addition opiates 
elicit apoptosis in human neurons via opioid receptor mechanism (Hu, Sheng, 
Lokensgard, & Peterson, 2002).  
In animal studies it has been determined that Mitragynine and two other 
components of Mitragyna speciosa (7-Hydroxymitragynine and MGM-9) develop 
tolerance and withdrawal signs through similar opioid mechanisms to morphine 
(Matsumoto et al., 2004; Matsumoto et al., 2005; Matsumoto et al., 2008; Tsuchiya 
et al., 2002; Watanabe et al., 1997). 
Ketum abuse has increased in recent years in Malaysia based on national drug 
reports by AADK. Despite of many studies about the effects of Mitragyna speciosa 
and its components in animals, human studies about ketum is scarce. Existing few 
human studies are descriptive studies outside a treatment setting. In the most recent 
study performed in northern parts of Peninsular Malaysia, users reported that they 
found ketum as an affordable way to reduce their addiction to opioids and it also 
eases the withdrawal symptoms for them. Although the majority of ketum users 
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reported difficulty in withdrawing from ketum, ketum withdrawal symptoms were 
less irritating than those from other drugs they used before (Vicknasingam, et al., 
2010b). There are no studies about ketum possible effects on the cognitive 
functioning in human. Hence a study on the neurocognitive function of ketum use in 
human will help identify if ketum use is safe and can be potentially used in treatment 
programs for drug users.  
 
1.7 Research Questions 
Based on the statement of problem this study will attempt to answer two 
questions below:  
a) What are the neurocognitive effects of ketum use in humans?  
b) What are the differences in neurocognitive functioning between ketum users 
and heroin users? 
 
1.8 Study Objectives 
a) To measure the neurocognitive function of ketum users in the northern parts 
of peninsular Malaysia 
b) To compare the neurocognitive function of ketum users and healthy non-drug 
users.  
c) To compare the neurocognitive function of ketum users and heroin users 
d) To compare the neurocognitive function of long term and short term ketum 
users 
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1.9 Scope of Study 
The northern states of peninsular Malaysia consist of four states (Perlis, Kedah, 
Penang and Perak). Based on the data provided by key informants, there are more 
ketum users in the states of Kedah, Perlis and Penang. For this reason this study was 
carried out in the states of Kedah, Perlis, and Penang.  
 
1.10 Significance of Study 
This study is the first known study about the neurocognitive functioning of 
ketum use in humans and will provide the neurocognitive profile with the emphasis 
on attention, visual memory, visuoperceptual abilities, visuoconstructional abilities, 
and executive functioning in ketum users and this will be compared with heroin 
users, and healthy non-addicts. It is hoped that this study will present insights about 
possible neurocognitive impairments related to ketum use.  
In addition, this study will also provide data on the neurocognitive function of heroin 
users in the country since there has been no known study to measure this in 
Malaysia. While, there are some studies about neurocognitive functioning in opiate 
users in other countries, it is clear that this function depends on many factors, like the 
type and the amount of drug, the stage when the participants were evaluated, and the 
cultural and regional factors.  
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1.11 Study Limitations 
Recruitment limitations: non-random sampling technique is limitation of the 
study. As the study was conducted in the community it was not possible to use 
probability sampling techniques. However, purposive sampling technique used 
together with chain referral sampling technique ensured that participants were 
representative across the three groups of samples.  
Another limitation is that it was difficult to recruit only heroin users as most 
heroin users in the country are poly drug users. Therefore the results of the heroin 
group may not reflect the effect of heroin on their neurocognitive function. 
Interviewing and testing limitation: Obtaining some of the information was 
based on the self report and data derived from this source is always biased by the 
impaired memory or even in healthy people due to recall bias. To ensure this 
limitation we used a Timeline Follow back (TLFB) method to obtain information 
regarding their drug use. Secondly, to perform the tests the environment requires 
being silent and well lightened with no or less distractions while in this study the 
interviews were done in small rooms or even outreach shelters for drug users and the 
researchers in some sites were unable to eliminated the distracting factors such as 
noise. During the study the researchers tried to minimize the effects of intoxication 
or withdrawal in heroin group participants while performing the tests. However, this 
is not possible to differentiate the participants who are between two ranges with 
varied degrees of concentration.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.0 Introduction  
In this chapter related and important literature in this study will be discussed. 
The terms and definitions used in this study, structural concepts, statistical facts, and 
relevant studies will all be included in this chapter.  
 
2.1 Drug Abuse 
The origin of the word drug is from a French word “drogue” which means “a 
dry substance” as dried herbs were widely used to prepare most of the 
pharmaceuticals at that time (Abadinsky, 2010). According to the World Health 
Organization (WHO) report published in 1981, drug is defined in the broadcast sense 
as “any chemical entity or mixture of entities, other than those required for the 
maintenance of normal health (like food), the administration of which alters 
biological function and possibly structure”. Some experts today prefer to use 
substance abuse instead of the term drug abuse as there is no distinctive definition for 
the term drug. 
Table 2.1 shows the DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders, 4
th
 Edition) definition of substance dependence. 
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Table 2.1 
 DSM-IV Diagnostic Criteria for Substance Dependence  
Substance Dependence:  
 
A maladaptive pattern of substance use leading to clinically significant impairment 
or distress, as manifested by three or more of the following occurring at any time in 
the same 12 month period: 
 
1. Tolerance, as defined by either of the following: 
(a) Need for markedly increased amounts of the substance to achieve 
intoxication or desired effect 
(b) Markedly diminished effect with continued use of the same amount of the 
substance 
2. Withdrawal , as manifested by either of the following: 
(a) The characteristic withdrawal syndrome for the substance 
(b) The same (closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
 
3. The substance is often taken in larger amounts or over a longer period than was 
intended 
 
4. A persistent desire or unsuccessful efforts to cut down or control substance use 
 
5. A great deal of time is spent in activities necessary to obtain the substance(e.g., 
visiting multiple doctors or driving long distances), to use the substance(e.g., chain-
smocking), or to recover from its effects 
 
6. Important social, occupational, or recreational activities given up or reduced 
because of substance use 
 
7. Continued substance use despite knowledge of having had a persistent or recurrent 
physical or psychological problem that is likely to be caused by or exacerbated by 
the substance (e.g., current cocaine use despite recognition of cocaine –induced 
depression, or continued drinking despite recognition that an ulcer was made worse 
by alcohol consumption) 
Specify if: 
With physiological dependence: evidence of tolerance or withdrawal (that is, either 
item [1] or [2] is present). 
 
Source.  Diagnostic and statistical manual of mental disorders, fourth edition, 1994 
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2.2 History of Ketum Use  
The local name for the leaves of the tropical plant Mitragyna speciosa Korth in 
Malaysia is ketum or biak. Mitragyna speciosa Korth is a medicinal plant native to 
Southeast Asia especially grown in central and southern parts of Thailand and 
northern states of peninsular Malaysia. In southern Thailand these leaves are usually 
called krathom (Chan et al., 2005).  
Use of ketum as a substitute for opiates in Malaysia was published for the first 
time in 1836 by Low and again mentioned in 1895 by Holmes who described ketum 
as Mitragyna speciosa (Jansen & Prast, 1988). In 1907, opium like effects of ketum 
apart from of its method of administration was described by Wray and it was stated 
that using large amounts of ketum products lead to stupor in users. In 1921, Field 
isolated Mitragynine alkaloid from Mitragyna speciosa in the University of 
Edinburgh. In 1930 Burkill stated the use of ketum in treatment of fever and as a 
wound poultice. He also recorded it as a suppressor for opiate withdrawal symptoms 
(Jansen & Prast, 1988).  
First serious pharmacological studies were performed on animals at the 
University of Cambridge by Grewal in 1932 (Grewal, 1932b) and in this report it was 
mentioned that Mitragynine is a central nervous system stimulant which resembles 
cocaine in effect and has been widely consumed in Thailand by farmers to enhance 
their work effectiveness. In his report ketum addicts were described as being thin, 
unhealthy with dry skin and dark lips (Grewal, 1932a).  
The first case of ketum addiction in human was reported by Thuan in 1957 and 
the effects again mentioned as “like cocaine”. This case was a chronic male ketum 
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user with withdrawal symptoms who stated that ketum habit caused no changes on 
his physical or mental condition (Jansen & Prast, 1988).  
In Thai narcotic book it was mentioned that ketum is weaker than morphine, 
less damaging than cocaine and causes milder withdrawal symptoms than opiates. It 
has both coca like stimulant and opiate and cannabis like depressive effects 
simultaneously. In this book medical uses of ketum in treating addicts in Thailand 
have been described (Jansen & Prast, 1988).  
By applying new analytic techniques in 1972 mitragynine was found to be 
comparable with codeine in animal studies in analgesic and cough suppressant 
effects with much less side effects than codeine. Great doses of mitragynine in cats 
had stimulating consequences which were different from what opiates caused. It was 
also found that mitragynine is much more active orally than subcutaneously 
suggesting that its metabolites might be the active analgesic (Jansen & Prast, 1988; 
Macko, Weisbach, & Douglas, 1972).  
 Ketum also has been used by local healers for treatment of medical problems 
such as diarrhea, diabetes mellitus, and also for improving blood circulation. 
Addictive nature of ketum, its withdrawal symptoms and its side effects of long-term 
use were reported in 1975 in Thailand (Suwanlert, 1975).  
Two types of ketum plant, one with red and another one with green veins in the 
leaves exist in Thailand and it is thought that the red vein variety plant has more 
biological activities (Chittrakarn, Sawangjaroen, Prasettho, Janchawee, & 
Keawpradub, 2008).  
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In recent years there has been an increase in the number of drug addicts who 
use ketum as their main drug of abuse. Compared to other drugs which are strictly 
controlled accessing ketum is easier and it is also more affordable because of its easy 
availability and significantly lower prices (Chan et al., 2005).  
 
2.3 Legal Aspects of Ketum Use 
In Thailand planting, possession, import and export of ketum are illegal since 
1943 (Assanangkornchai, Muekthong, Sam-angsri, & Pattanasattayawong, 2007). 
While in Malaysia ketum use was only banned since 2003. In Malaysia planting of 
the tree is not an offence but as Mitragynine (the major component of ketum ) was 
listed in the first and third schedule of the poisons act 1952, possession and selling 
any ketum preparations containing Mitragynine carries a  fine of RM 10,000 ( US$1 
= 3 RM), a four year jail sentence or both (Chan et al., 2005).  
Ketum detection in different types of its products (drinks, powdered or 
macerated leaves) can be made only by identifying the presence of Mitragynine by 
specific gas chromatography methods (Chan et al., 2005).  
Although ketum use is illegal or controlled in some countries including 
Malaysia, Thailand, Myanmar, south Korea, Australia, new Zealand, Finland, 
Germany, Romania, and Denmark, its use in most of other countries in the world is 
uncontrolled and ketum can be purchased online (Chittrakarn et al., 2008; Erowid, 
2004).  
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2.4 Pharmacological Studies 
The earliest formal pharmacological studies were carried out in 1932 and the 
cocaine like stimulant effect of mitragynine was identified (Grewal, 1932b). In 1960 
applying new analytic methods, several indole alkaloids were isolated from ketum 
leaves and in 1978 Shellard et al, isolated more than twenty alkaloids of Mitragyna 
speciosa Korth (Jansen & Prast, 1988; Takayama, 2004).  
Mitragynine found to be the major component with about 66% of basic extract 
of Mitragyna speciosa Korth (Figure 2.1). 7-Hydroxymitragynine is the minor 
constituent (2%) of Mitragyna speciosa with higher opioid receptor binding affinity 
than mitragynine and has long been used in traditional Thai medicine for its opiate-
like effect (Takayama, 2004; Takayama et al., 2002).  
Mitragynine was found to be an opioid receptor agonist that inhibits the 
electrically stimulated contraction in guinea-pig ileum and gastric acid secretion in 
rats (Tsuchiya et al., 2002; Watanabe et al., 1997; Yamamoto et al., 1999). 
Mitragynine also showed morphine-like antinociceptive activity in in-vitro and in-
vivo experiments through supraspinal µ and δ opioid receptors (Matsumoto et al., 
1996; Thongpradichote et al., 1998; Tohda et al., 1997). Later studies showed that 
analgesic activity of methanol and alkaloid extracts of ketum is partly related to 
opioid receptors in supraspinal opioid system (Reanmongkol et al., 2007). 
Mitragynine inhibits the pain transduction in guinea pigs vas deferens by blocking 
the calcium channels while opioid receptors are not involved in this process 
(Matsumoto et al., 2005b).  
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              Mitragynine                                                                7-hydroxymitragynine 
Figure 2.1. Chemical structures of mitragynine and 7-hydroxymitragynine 
Source.  (Matsumoto et al., 2004) 
 
Mitragynine pseudoindoxyl (a derivative compound of mitragynine) was much 
more potent opioid agonist than morphine but had less antinociceptive effect 
comparing with morphine (Takayama, et al., 2002; Yamamoto, et al., 1999).  
The most potent opioid agonistic effect is found in MGM-9 [(E)-methyl 2-(3-
ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-
methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate] which produces more 
antinociceptive effects and less adverse effects than morphine (Matsumoto et al., 
2008). 
7-hydroxymitragynine has opioid agonistic effect through µ, δ, and κ opioid 
receptors but receptor-binding analyzes showed higher affinity of this constituent for 
µ opioid receptors than other types of opioid receptors. 7-hydroxymitragynine 
exhibits higher antinociceptive effect than that of morphine, especially with oral 
administrations (Matsumoto et al., 2004; Takayama et al., 2002). 7-
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hydroxymitragynine develops tolerance and withdrawal signs through similar opioid 
mechanisms for morphine (Matsumoto et al., 2005a).  
Administration of Mitragyna speciosa aqueous and alkaloid extract induces 
antidepressant effect maybe through serotonin or noradrenalin neurotransmitters and 
also reduces the ethanol withdrawal symptoms in mice. These results in animal 
studies suggest that mitragynine could have a role in managing the depressive 
disorders     (Idayu et al., 2011; Kumarnsit, Keawpradub, & Nuankaew, 2007a; 
Kumarnist, Vongvatcharanon,  Keawpradub, & Intasaro, 2007b).  
Acute and chronic administration of certain doses of Mitragyna speciosa 
alkaloid extract significantly decline voluntary food and water consumption in rats. 
Gaining body weight is considerably suppressed by chronic administration of 
alkaloid extracts. These results confirm the imipramine like anorectic effect of 
Mitragyna speciosa extract without making any clear tolerance (Kumarnsit et al., 
2006). 
 Inhibitory effects of Mitragyna speciosa extract on food and water intake have 
different underline mechanisms. Rather than opioid related mechanism that is 
thought to mediate the food intake inhibition effect of Mitragyna speciosa extract, as 
water intake is inhibited by activation of adrenergic and serotonergic systems, it is 
suggested that Mitragyna speciosa extract may act on these central systems to induce 
its water intake suppression effect. All together it is proposed that food intake 
suppressing effect of Mitragyna speciosa extract indirectly reduces the blood glucose 
level (Kumarnsit et al., 2006).  
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Ketum has been used by traditional healers to treat diarrhea and some 
gastrointestinal infections (Chittrakarn et al., 2008). Ketum methanolic extract had 
been used to treat castor oil induced diarrhea in rats and results were compared with 
the effects of loperamide (a µ opioid receptor agonist) as a standard anti-diarrheal 
drug and controls. Ketum methanolic extract reduced the severity of diarrhea, 
intestinal transit and fecal weight. The anti-diarrheal effect of ketum methanolic 
extract was same as that of loperamide but this effect was not antagonized by 
naloxone (Chittrakarn et al., 2008).  
In fourteen days of acute toxicity evaluation no mortality or toxicity symptoms 
happened in rats given the toxic level of Mitragyna speciosa extract. Minimal 
changes in respiratory and nervous system were happened which were rapidly 
reversed. Single dose oral administration of Mitragyna speciosa extract in rats 
caused no significant changes in body weight, food and water consumption, absolute 
organ weight, hematological parameters and hippocampal neurons. However, 
significant increase in blood pressure, increased levels of ALT, LDH, cholesterol, 
urea, and creatinine in biochemistry assessments and abnormal liver cell morphology 
were observed (Harizal et al., 2010). 
Ketum has been used traditionally by workers to manage the muscle pain and 
strain. Mitragyna speciosa methanol extracts reduced muscle contractions by a 
greater effect on neuromuscular junction than on the skeletal muscle or somatic 
nerve (Chittrakarn et al., 2010). 
In animal behavioral studies, methanol and alkaloid extracts of Mitragyna 
speciosa leaves had no significant effect on pentobarbital-induced sleep or in 
locomotor activity in mice and rats (Moklas et al., 2008; Reanmongkol et al., 2007).  
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In a recent behavioral study, object placement task which is a valid animal 
model for assessing object recognition in mice, was administered to evaluate the 
effect of mitragynine on this cognitive function and results showed significant 
impairments in the performance of mice (Apryani et al., 2010) 
 
2.5 Ketum Studies in Human 
In a study conducted in Thailand in 1975 by Suwanlert, thirty ketum users who 
had been using ketum for more than five years were studied. Most dominant aspect 
of ketum addiction in this group was strong desire to do manual work. The leaves 
were chewed freshly or taken as powder by majority (90 %) of ketum users and salt 
was added to prevent constipation. They chewed ketum leaves three to ten times a 
day and reported that stimulant effects began in five to ten minutes. It was reported 
by almost all of the users that they had become addicted to ketum (Suwanlert, 1975). 
Several side effects were reported by ketum users including mouth dryness, anorexia, 
weight loss, and constipation. In long term ketum users, typical withdrawal 
symptoms like violent behavior, rhinorrhea, body aching and jerky movements were 
reported (Jansen & Prast, 1988; Suwanlert, 1975).  
In another study in Thailand in 2007, 149 regularly ketum users who had been 
using ketum daily for more than five years, 168 irregular users (less than once a 
week in social circumstances or for medical purposes), and 116 nonusers  
participated and patterns and consequences of ketum use was studied in them. Most 
of the ketum users participated in the study (90.22%) mentioned that they worked 
harder and longer, felt happier and had a better mood following the consumption of 
ketum and only 4-14% of them reported negative effects. Among the negative effects 
